Methods of assessing a risk of developing necrotizing meningoencephalitis

An isolated nucleic acid molecule comprising at least one nucleic acid segment of SEQ ID NO:

• 1, wherein said segment consisting of nucleotide positions 4,713,392 to 8,834,652 of SEQ ID NO:
• 1 comprises one or more SNP haplotype blocks represented by:
• SEQ ID NO:
• 3 at position 4713392-4821633, SEQ ID NO:4 at position 4836721-4923170, SEQ ID NO:5 at position 4938082-5088561, SEQ ID NO:6 at position 5108726-5364188, SEQ ID NO:7 at position 5491709-5672682, SEQ ID NO:8 at position 5710832-6078099, SEQ ID NO:9 at position 6149213-6342204, SEQ ID NO:10 at position 6492201-6982375, SEQ ID NO:11 at position 6992493-7270218, SEQ ID NO:12 at position 7338759-7350261, SEQ ID NO:13 at position 7384390-7643147, SEQ ID NO:14 at position 7725530-7830733, SEQ ID NO:15 at position 7927872-7944953, SEQ ID NO:16 at position 7950821-8158994, SEQ ID NO:17 at position 8208369-8265940, SEQ ID NO:18 at position 8327142-8386063, SEQ ID NO:19 at position 8429601-8533350, SEQ ID NO:20 at position 8546686-8713747, and SEQ ID NO:21 at position 8719506-8834652 on Chromosome 12.

An isolated nucleic acid molecule comprising at least one nucleic acid segment of SEQ ID NO:

• 2, wherein said segment consisting of nucleotide positions 31,736,206 to 32,225,068 of SEQ ID NO:
• 2 comprises one or more SNP haplotype blocks represented by:
• SEQ ID NO:
• 24 at position 31,736,206 to 31,795,128, SEQ ID NO:
• 25 at position 31,866,373 to 31,883,390, SEQ ID NO:
• 26 at position 31,971,609 to 32,009,283, and SEQ ID NO:
• 27 at position 32,183,184 to 32,225,068 on Chromosome 8.

A method of classifying a subject to an NME disease risk group, comprising:

• receiving a nucleic acid-containing sample from the subject;
• detecting the presence of at least one haplotype block listed in Table 3 and Table 4, wherein the haplotype block comprises at least two linked markers within the haplotype block, wherein the haplotype block is represented by:
• SEQ ID NO:
• 3 at position 4713392-4821633, SEQ ID NO:4 at position 4836721-4923170, SEQ ID NO:5 at position 4938082-5088561, SEQ ID NO:6 at position 5108726-5364188, SEQ ID NO:7 at position 5491709-5672682, SEQ ID NO:8 at position 5710832-6078099, SEQ ID NO:9 at position 6149213-6342204, SEQ ID NO:10 at position 6492201-6982375, SEQ ID NO:11 at position 6992493-7270218, SEQ ID NO:12 at position 7338759-7350261, SEQ ID NO:13 at position 7384390-7643147, SEQ ID NO:14 at position 7725530-7830733, SEQ ID NO:15 at position 7927872-7944953, SEQ ID NO:16 at position 7950821-8158994, SEQ ID NO:17 at position 8208369-8265940, SEQ ID NO:18 at position 8327142-8386063, SEQ ID NO:19 at position 8429601-8533350, SEQ ID NO:20 at position 8546686-8713747, and SEQ ID NO:21 at position 8719506-8834652 on Chromosome 12, and at position 32,183,184 to 32,225,068 on Chromosome 8;
• and
• classifying the subject into a risk group based upon the presence of at least one haplotype block, whereas classifying the subject into a non-risk group based upon the absence of any haplotype block.